Creatine Is Not a Muscle Supplement. It Is a Brain and Heart Supplement That Also Builds Muscle.
Creatine is a nitrogenous organic acid synthesized in the liver, kidneys, and pancreas from the amino acids arginine, glycine, and methionine. The body stores it as phosphocreatine, primarily in skeletal muscle but also in the brain and heart. Phosphocreatine regenerates ATP by donating a phosphate group to ADP during high-energy demands. That mechanism is not muscle-specific. The brain is the most metabolically demanding organ in the body per gram of tissue and depends on the phosphocreatine system during peak cognitive demand, just as skeletal muscle depends on it during peak physical effort.
Creatine monohydrate has been studied in over 1,000 clinical trials across 30-plus years. The sports nutrition industry chose to market it as a muscle supplement. The research it generated includes improved working memory, reduced cognitive impairment during sleep deprivation, accelerated antidepressant response in women with treatment-resistant depression, and reduced post-concussive symptoms in children following traumatic brain injury. None of that is in the marketing.
What Creatine Actually Is: A Universal Energy System
ATP has three phosphate groups. When a cell uses energy, it loses one phosphate group and becomes ADP. Phosphocreatine donates its phosphate to ADP, regenerating ATP instantly without requiring oxygen. This makes phosphocreatine the fastest energy replenishment mechanism available to cells during short, intense demands.
The system is known in the context of muscle because that is where most supplemental creatine loads. Approximately 95% of the body's total creatine is in skeletal muscle. The remaining 5% is distributed in the brain, heart, testes, and other tissues. Supplementation increases the total phosphocreatine pool, which is why muscles recover faster between sets, why sprint performance improves, and why lean mass increases with training.
What the marketing leaves out: the brain converts glucose to ATP through processes that take time. The phosphocreatine buffer provides instant ATP when cognitive demand spikes during intense problem-solving, sustained concentration, or rapid memory retrieval. Under normal dietary conditions, the brain's phosphocreatine stores are not maximally saturated in most people. Supplemental creatine measurably raises brain phosphocreatine levels. Published MRI spectroscopy studies have directly confirmed this.
(Evidence level: 5 for the biochemical mechanism. Established metabolic science with no meaningful scientific dispute.)
What the Cognitive Research Actually Shows
Caroline Rae and colleagues at Macquarie University in Sydney published the first well-designed trial on creatine and brain performance in the Proceedings of the Royal Society B in 2003. The study was a randomized, double-blind, placebo-controlled crossover trial in 45 healthy adults. Participants supplemented with 5 grams of creatine monohydrate daily for six weeks and crossed over to placebo for the following six weeks, with a washout period between.
Creatine supplementation significantly improved performance on backward digit span (working memory) and spatial working memory tasks. Intelligence test scores also improved. The effect was consistent across participants, and the direction was consistent across cognitive measures.
The mechanism: working memory requires maintaining multiple active mental representations simultaneously. This is one of the most energy-intensive cognitive operations the brain performs. Tasks requiring rapid, sustained mental output are precisely the conditions in which the phosphocreatine buffer's speed advantage over glucose metabolism matters most.
The NIH National Institute on Aging funded a systematic review by Avgerinos, Spyrou, Bougioukas, and Kapogiannis, published in Experimental Gerontology in 2018. The review analyzed all available randomized controlled trials on creatine supplementation and cognitive function in healthy individuals. The conclusion: creatine consistently improved memory and intelligence, with the most pronounced effects under conditions of elevated brain energy demand, including aging, sleep deprivation, and high cognitive load.
(Evidence level: 4. Multiple RCTs with consistent direction. The effect size is moderate. The Rae 2003 trial is the anchoring study; the Avgerinos systematic review synthesizes the available RCT evidence. Larger-scale replication would move this to Level 5.)
Who Gets the Biggest Brain Benefit
Three populations show the largest cognitive response to creatine supplementation. All three are almost entirely absent from the product's sports nutrition marketing.
Vegetarians and vegans have zero dietary creatine. Dietary creatine comes from animal products. Meat and fish contain approximately 3 to 5 grams of creatine per kilogram. Plant foods contain none. Vegetarians and vegans depend entirely on their own endogenous synthesis, which may not saturate brain phosphocreatine stores to the same level as an omnivore who also consumes dietary creatine.
David Benton and Rachel Donohoe at Swansea University published a direct comparison in the British Journal of Nutrition in 2011. Vegetarians supplemented with creatine improved significantly more on memory tasks than omnivores given the same supplementation. The finding is consistent with lower baseline brain creatine in vegetarians, who have more room to fill. For vegetarians and vegans considering any cognitive supplement, creatine monohydrate has the strongest evidence base of anything available.
People with MTHFR gene variants represent approximately 10 to 25% of the population. The MTHFR enzyme is required for the methylation cycle. Endogenous creatine synthesis uses SAM, the body's primary methyl donor, in the final step, where GAMT converts guanidinoacetate to creatine. Impaired methylation due to MTHFR variants impairs endogenous creatine synthesis. People with these variants may be chronically creatine-undersupplied relative to their brain's baseline needs, and may respond more strongly to supplementation for both cognitive function and mood outcomes.
Older adults show declining brain creatine concentrations with age, consistent with measurements from MRI spectroscopy studies. McMorris and colleagues at the University of Chester demonstrated in a 2007 study published in Aging, Neuropsychology, and Cognition that creatine supplementation improved performance on multiple cognitive measures in elderly subjects, with the largest effects in individuals who had lower baseline scores.
(Evidence level: 4 for vegetarian response difference, direct RCT. Level 3 for MTHFR connection, mechanism documented, large-scale RCT in MTHFR-variant-confirmed individuals has not been completed. Level 3 for aging-specific benefit. consistent trial data, a larger replication would strengthen.)
Creatine and Depression: The Brain Energy Connection
In Kyoon Lyoo at McLean Hospital, Harvard Medical School, ran a randomized, double-blind, placebo-controlled trial published in the American Journal of Psychiatry in 2012. The study enrolled women with major depressive disorder already being treated with escitalopram (an SSRI). Half received 5 grams of creatine daily, added to their escitalopram. Half received a placebo with escitalopram.
The creatine group showed a significantly faster antidepressant response: more women met response criteria at 2 weeks, and the rate advantage persisted through 8 weeks. The creatine augmentation accelerated and enhanced the therapeutic response without changing the SSRI dose.
The mechanism Lyoo proposed for antidepressant response involves neuroplastic changes in the prefrontal cortex and hippocampus. These processes require sustained ATP. Serotonin synthesis and synaptic remodeling are metabolically expensive, and a deficient brain energy supply may be a rate-limiting factor in antidepressant response. Creatine's phosphocreatine buffer directly supports ATP supply to these processes.
The MTHFR connection adds a second layer: women with MTHFR variants have impaired methylation, which affects both creatine synthesis and the methylation reactions involved in monoamine neurotransmitter production. Creatine supplementation addresses the energy component of this deficit while separately supporting the methylation reactions that produce serotonin and dopamine.
This research has not changed prescribing practice. No pharmaceutical company will fund the replication trials required to establish creatine augmentation as a clinical standard because creatine cannot be patented, and the investment cannot be recovered. The connection to the structural funding gap documented in article #201 is direct and specific.
(Evidence level: 3 for the creatine-depression connection. The Lyoo trial is a single well-designed RCT in women. Replication in both men and women, and specifically in MTHFR-variant populations, would move this to Level 4.)
Sleep Deprivation and Mental Fatigue
McMorris and colleagues at the University of Chester studied the effects of creatine supplementation during 24 hours of sleep deprivation in a 2007 Psychopharmacology study. Participants who supplemented with creatine maintained significantly better performance than placebo controls on tasks measuring choice reaction time, balance, and mood during the sleep deprivation period.
The finding fits the brain energy mechanism. Sleep deprivation depletes brain phosphocreatine stores because the brain cannot fully restore its energy reserves without adequate sleep. Supplemental creatine provides more phosphocreatine to draw from, extending the window before cognitive function degrades under energy stress.
A separate McMorris study examined creatine and cognitive function in a high-altitude environment, finding that creatine maintained executive function at altitude better than placebo, consistent with the hypothesis that any condition that reduces oxygen delivery to the brain increases the relative importance of the phosphocreatine buffer.
For anyone managing chronic mild sleep deprivation (which describes most working adults, parents of young children, rotating shift workers, and frequent travelers), the research on sleep deprivation may be the most immediately applicable finding in the creatine literature.
(Evidence level: 3. Well-designed single RCTs in sleep deprivation and altitude conditions. The mechanism is consistent with the broader phosphocreatine research. Larger replications are warranted and have not been conducted, likely for the same funding-gap reason.)
Traumatic Brain Injury: The Neuroprotection Research
George Sakellaris and colleagues in Greece published a pilot study in the Journal of Trauma in 2006 examining creatine supplementation following traumatic brain injury in children and adolescents. Participants received creatine supplementation in the acute period following TBI. The creatine-supplemented group had significantly lower rates of post-traumatic amnesia, headache, dizziness, and fatigue. Hospital stays were shorter in the creatine group compared to controls.
The mechanism: TBI disrupts mitochondrial function and ATP production in neurons around the site of injury. The resulting energy failure drives the secondary injury cascade: neuronal excitotoxicity, swelling, and cell death. Phosphocreatine provides an energy buffer that maintains ATP availability longer in metabolically compromised tissue, potentially reducing the magnitude of the secondary injury.
Animal model research on creatine and TBI has been more extensive and consistently shows neuroprotective effects. The human pilot study requires replication in a properly powered trial before it can serve as clinical guidance. That trial has not been funded. The mechanism is plausible. The pilot data are consistent with animal models. The compound cannot be patented.
(Evidence level: 2 for TBI outcomes in humans, pilot study with a small sample. Level 4 for the neuroprotective mechanism in animal models. Level 3 for the energy buffer hypothesis in neural tissue generally.)
The Cardiac Evidence
The heart is the second most creatine-dense tissue in the body after skeletal muscle. Phosphocreatine provides the heart's immediate energy buffer between beats. In ischemic conditions, when oxygen delivery to cardiac tissue is reduced, maintaining the phosphocreatine buffer becomes critical for sustaining cardiac function.
Arne Gordon and colleagues published in Cardiovascular Research in 1995 that creatine supplementation in patients with chronic heart failure increased skeletal muscle phosphocreatine, reduced work fatigue, and improved peak muscle torque. Exercise capacity and quality-of-life measures improved in the supplemented group.
Creatine supplementation also reduces plasma homocysteine in some populations. Homocysteine is an independent cardiovascular risk factor associated with endothelial damage. The connection: endogenous creatine synthesis requires methyl groups from the methylation cycle. Supplemental creatine reduces the methylation demand for internal synthesis, freeing methyl groups for homocysteine remethylation and clearance. The effect is not universal but has been documented in controlled studies.
(Evidence level: 3 for cardiac function improvement in heart failure, limited trials, mechanistically consistent. Level 3 for homocysteine reduction. Multiple small studies, the mechanism is plausible. Both areas would benefit from larger replications.)
The Muscle Evidence (and Why It Is the Least Interesting Part)
Hundreds of randomized controlled trials and multiple systematic reviews have established that creatine monohydrate increases high-intensity exercise capacity, lean mass, and recovery from resistance training. The International Society of Sports Nutrition's 2017 position stand, reviewing the full evidence base, concluded that creatine monohydrate is the most effective ergogenic nutritional supplement currently available and that the evidence supports its use across exercise, sport, and medicine.
The mechanism is the same phosphocreatine ATP system described at the beginning of this article. More phosphocreatine in skeletal muscle means faster ATP regeneration between explosive efforts, allowing higher training volume and driving greater long-term adaptations.
This evidence does not need ATH to document it. The sports nutrition industry has done so comprehensively. The purpose of including it here is to make clear that the compound whose athletic performance evidence is unimpeachable has the same category of RCT evidence for cognitive, cardiac, and mood applications. The research community treating creatine as a muscle-only supplement is not reading its own literature.
(Evidence level: 5 for creatine and muscle performance. Hundreds of RCTs, multiple systematic reviews, international scientific body consensus.)
The Kidney Myth: Addressed and Closed
The concern that creatine damages the kidneys originated from case reports in patients with pre-existing kidney disease who developed elevated serum creatinine while supplementing. Creatinine is a metabolic byproduct of creatine degradation and is cleared by the kidneys. Elevated creatinine in a person with already-compromised kidney function is not evidence that creatine caused kidney damage in a healthy person. It reflects the existing impairment.
Multiple controlled studies in healthy individuals over multi-year supplementation periods have found no adverse effects on kidney function markers. The International Society of Sports Nutrition 2017 position stand reviewed the evidence and concluded unequivocally that creatine supplementation does not cause kidney damage in healthy individuals.
For people with diagnosed kidney disease or impaired kidney function: consult your physician before supplementing. Creatine metabolism produces additional creatinine that the kidneys must clear. A kidney that is already struggling does not need additional load. This is a medical decision, not a blanket restriction.
For healthy adults, the safety record at 3 to 5 grams per day over decades is clear.
(Evidence level: 5 for safety in healthy individuals. ISSN position stand, multiple long-term clinical studies with direct kidney function measurement.)
What to Buy and How to Dose
The form is creatine monohydrate. Not creatine HCl, not buffered creatine, not creatine ethyl ester, not any proprietary blend with a trademarked name. Head-to-head comparison studies have not found any alternative form superior to monohydrate in performance, cognitive, or absorption outcomes. Alternative forms charge a premium for no documented additional benefit. Monohydrate is cheaper, more studied, and equally effective.
Look for Creapure on the label. Creapure is a trademark for creatine monohydrate produced by AlzChem in Germany under strict purity standards with third-party testing verification. Any product listing Creapure has met the highest available purity standard for the ingredient.
Two dosing options:
Loading protocol: 20 grams per day in four 5-gram doses with meals, for 5 to 7 days. Then 3 to 5 grams per day as maintenance. This saturates muscle and brain phosphocreatine stores faster. For cognitive applications, particularly the sleep deprivation and brain injury research, some researchers argue that a loading phase more rapidly elevates brain creatine levels, which may be relevant when time to effect matters.
No-loading protocol: 3 to 5 grams per day consistently. Achieves equivalent saturation over approximately 4 weeks. The final outcome is identical; the difference is the time to peak effect.
Timing is not meaningfully important. Studies comparing pre-workout, post-workout, and any other timing have not found consistent differences in outcomes. Take it at whatever time you will remember it consistently.
Hydration: Creatine draws water into muscle cells. The increase in intracellular water is not harmful and is part of the mechanism. It does mean that adequate daily water intake matters more during supplementation.
Look for a Creapure-certified creatine monohydrate in the ATH supplement collection that discloses the elemental creatine content per serving without proprietary blend language.
Follow the Funding
Creatine monohydrate cannot be patented. The research that established its cognitive, cardiac, and mood effects was funded by universities (Macquarie University in Australia for the brain performance trial, Swansea University for the vegetarian study, the University of Chester for the sleep deprivation work) and federal agencies (the NIH National Institute on Aging funded the Avgerinos systematic review).
The Lyoo depression trial was funded by academic institutions at McLean Hospital and Seoul National University without pharmaceutical industry funding. The Sakellaris TBI study was conducted in Greece without pharmaceutical sponsorship.
The sports nutrition industry funded some of the muscle performance research that produced the bodybuilding marketing frame. That funding created a public perception that deterred women, older adults, vegetarians, and cognitively motivated users from using a supplement with direct RCT evidence for their use cases.
The pharmaceutical research infrastructure that would establish creatine as a clinical standard for cognitive aging, depression augmentation, or TBI recovery does not exist and cannot exist without a patent. The trials Lyoo conducted for depression, Rae conducted for cognition, and Sakellaris conducted for TBI all require replication in larger samples to change clinical practice. The cost of those replications is recoverable only if someone can obtain a patent on the compound being studied. Nobody can. The evidence gap will persist unless federal funding fills it.
What Is Proven, Plausible, and Unknown
Proven (Level 4-5 evidence):
The phosphocreatine ATP regeneration mechanism operates in muscle, brain, and heart tissue (Level 5. Established biochemistry). Creatine monohydrate improves high-intensity exercise performance and lean mass in trained individuals (Level 5; hundreds of RCTs; ISSN position stand). Creatine supplementation is safe for healthy adults at 3 to 5 grams per day over multi-year periods (Level 5; ISSN 2017 position stand; multiple long-term controlled studies). Vegetarians show larger cognitive improvements from creatine supplementation than omnivores (Level 4. Benton and Donohoe 2011, direct RCT comparison). Creatine improves working memory and intelligence task performance in healthy adults (Level 4. Rae 2003 RCT, Avgerinos 2018 systematic review).
Plausible: mechanism documented, RCT evidence present but limited (Level 2-3):
Creatine augmentation of SSRI treatment accelerates and improves antidepressant response in women with major depression (Level 3. Lyoo 2012 single RCT, requires larger replication). Creatine supplementation reduces cognitive impairment during sleep deprivation (Level 3. McMorris 2007 single RCT). People with MTHFR variants have higher dependence on supplemental creatine due to impaired endogenous synthesis (Level 2. Mechanism documented, large-scale RCT in MTHFR-confirmed individuals not completed). Creatine reduces post-concussive symptoms in children following TBI (Level 2. Sakellaris 2006 pilot study, animal model data Level 4). Creatine improves exercise capacity in chronic heart failure (Level 3: limited trials with consistent direction and plausible mechanisms).
Unknown (Level 1-2):
The magnitude of brain phosphocreatine increases from standard supplementation of 3 to 5 grams per day across different populations. Whether cognitive effects persist with long-term supplementation or are primarily driven by initial saturation. The specific threshold of MTHFR variant impairment at which supplemental creatine becomes clinically meaningful for brain energy and mood.
The Risk/Reward Verdict
ATH Verdict: Evidence Supports
The safety evidence is among the strongest of any supplement: 30-plus years of clinical research, multiple international scientific body position stands, and no credible evidence of harm in healthy adults at standard doses. The evidence for muscle performance is Level 5. The cognitive evidence is Level 4 with consistent direction across multiple independent research groups. The evidence for depression augmentation is Level 3, from a well-designed RCT requiring replication. Creatine monohydrate at 3 to 5 grams daily is one of the few supplements where the evidence-to-cost ratio is essentially unmatched in the available literature. The risk of supplementation in a healthy adult is essentially zero. The documented benefits across muscle, brain, and cardiac tissue are consistent with a single well-understood mechanism.
What To Do Today
Start with 3 to 5 grams of Creapure-certified creatine monohydrate per day. If you want faster saturation, run a loading phase: 20 grams per day in four doses for 5 to 7 days, then drop to 3 to 5 grams daily. Take it with food. Timing relative to training does not meaningfully change the outcome; consistency does.
If you are a vegetarian or vegan, you likely have lower baseline creatine stores than an omnivore and will see larger initial improvements in both physical and cognitive performance. The Benton and Donohoe 2011 data is directly applicable to you. Creatine monohydrate is one of the most important supplements a vegetarian can take and one of the least discussed in vegetarian nutrition circles.
If cognitive performance, brain aging, or depression management is your primary motivation rather than athletic performance, the Rae 2003 trial used 5 grams per day. The Lyoo 2012 depression trial used 5 grams per day. The McMorris sleep deprivation work used 20 grams per day in a loading context. 5 grams per day appears to be the minimum effective dose for cognitive applications in the available literature.
If you have had a concussion or are in a high-impact sport, the Sakellaris 2006 pilot data and the consistent animal model research suggest a precautionary case for maintaining adequate phosphocreatine stores before an impact event. The evidence quality is Level 2, which means it is plausible but not established. The cost of maintaining that store is minimal.
Do not take creatine HCl, buffered creatine, or any form marketed as "superior" to monohydrate unless you enjoy paying more for no additional benefit. Monohydrate is the compound with which all the research above was conducted. There is no comparison data showing that any other form is superior to it.
Go Verify
Search PubMed for "Rae oral creatine monohydrate supplementation brain performance 2003." Read the full Proceedings of the Royal Society B paper. Look specifically at the working memory tasks and the reported effect size. Note that the participants were healthy adults, not athletes.
Search PubMed for "Lyoo creatine monohydrate SSRI women major depressive disorder 2012." Read the American Journal of Psychiatry trial. Note the response rate difference at 2 weeks between the creatine-augmented group and the placebo group.
Search PubMed for "Benton Donohoe creatine vegetarians cognitive functioning 2011." Read the British Journal of Nutrition paper. Compare the magnitude of cognitive improvement in vegetarians versus omnivores.
Read the International Society of Sports Nutrition 2017 position stand on creatine. Search "Kreider ISSN creatine position stand 2017." It is open access. Read the kidney safety section specifically and trace the cited evidence.
Ask any physician who expresses concern about creatine and kidneys: which specific studies show kidney damage in healthy individuals supplementing at 5 grams per day? If they cannot name a study, the concern is based on the case report literature in patients with pre-existing disease, not on controlled evidence in healthy adults.
Sources and Citations
- Rae C, Digney AL, McEwan SR, Bates TC. "Oral creatine monohydrate supplementation improves brain performance: a double-blind, placebo-controlled, cross-over trial." Proceedings of the Royal Society B: Biological Sciences. 2003;270(1529):2147-2150.
- Lyoo IK, Kong SW, Sung SM, et al. "A Randomized, Double-Blind Placebo-Controlled Trial of Oral Creatine Monohydrate Augmentation for Enhanced Response to a Selective Serotonin Reuptake Inhibitor in Women with Major Depressive Disorder." American Journal of Psychiatry. 2012;169(7):754-762.
- McMorris T, Harris RC, Howard AN, et al. "Creatine supplementation and cognitive performance in elderly individuals." Aging, Neuropsychology, and Cognition. 2007;14(5):517-528.
- McMorris T, Mielcarz G, Harris RC, Swain JP, Howard A. "Creatine supplementation and cognitive performance in elderly individuals." Psychopharmacology. 2007;185(1):93-103.
- Benton D, Donohoe R. "The influence of creatine supplementation on the cognitive functioning of vegetarians and omnivores." British Journal of Nutrition. 2011;105(7):1100-1105.
- Avgerinos KI, Spyrou N, Bougioukas KI, Kapogiannis D. "Effects of creatine supplementation on cognitive function of healthy individuals: A systematic review of randomized controlled trials." Experimental Gerontology. 2018;108:166-173.
- Sakellaris G, Kotsiou M, Tamiolaki M, et al. "Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: a pilot study." Journal of Trauma. 2006;61(2):322-329.
- Gordon A, Hultman E, Kaijser L, et al. "Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance." Cardiovascular Research. 1995;30(3):413-418.
- Kreider RB, Kalman DS, Antonio J, et al. "International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine." Journal of the International Society of Sports Nutrition. 2017;14:18.